These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39403930)

  • 1. Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events.
    Haugh AM; Daud AI
    J Clin Invest; 2024 Oct; 134(20):. PubMed ID: 39403930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
    Kao CJ; Charmsaz S; Alden SL; Brancati M; Li HL; Balaji A; Munjal K; Howe K; Mitchell S; Leatherman J; Griffin E; Nakazawa M; Tsai HL; Danilova L; Thoburn C; Gizzi J; Gross NE; Hernandez A; Coyne EM; Shin SM; Babu JS; Apostol GW; Durham J; Christmas BJ; Konig MF; Lipson EJ; Naidoo J; Cappelli LC; Pabani A; Ged Y; Baretti M; Brahmer J; Hoffman-Censits J; Seiwert TY; Garonce-Hediger R; Guha A; Bansal S; Tang L; Jaffee EM; Chandler GS; Mohindra R; Ho WJ; Yarchoan M
    J Clin Invest; 2024 Aug; 134(20):. PubMed ID: 39403935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
    van Eijs MJM; Verheijden RJ; van der Wees SA; Nierkens S; van Lindert ASR; Suijkerbuijk KPM; van Wijk F;
    Cancer Immunol Immunother; 2023 Dec; 72(12):4049-4064. PubMed ID: 37794264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
    Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
    Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
    Franken A; Van Mol P; Vanmassenhove S; Donders E; Schepers R; Van Brussel T; Dooms C; Yserbyt J; De Crem N; Testelmans D; De Wever W; Nackaerts K; Vansteenkiste J; Vos R; Humblet-Baron S; Lambrechts D; Wauters E
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
    Berner F; Flatz L
    Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
    Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
    Front Immunol; 2022; 13():987568. PubMed ID: 36159840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
    Nuñez NG; Berner F; Friebel E; Unger S; Wyss N; Gomez JM; Purde MT; Niederer R; Porsch M; Lichtensteiger C; Kramer R; Erdmann M; Schmitt C; Heinzerling L; Abdou MT; Karbach J; Schadendorf D; Zimmer L; Ugurel S; Klümper N; Hölzel M; Power L; Kreutmair S; Capone M; Madonna G; Cevhertas L; Heider A; Amaral T; Hasan Ali O; Bomze D; Dimitriou F; Diem S; Ascierto PA; Dummer R; Jäger E; Driessen C; Levesque MP; van de Veen W; Joerger M; Früh M; Becher B; Flatz L
    Med; 2023 Feb; 4(2):113-129.e7. PubMed ID: 36693381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors.
    Wang M; Zhai X; Li J; Guan J; Xu S; Li Y; Zhu H
    Front Immunol; 2021; 12():670391. PubMed ID: 34367136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Ju M; Zhang J; Deng Z; Wei M; Ma L; Chen T; Zhao L
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39089739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF in the era of immune checkpoint inhibitors: friend or foe?
    Chen AY; Wolchok JD; Bass AR
    Nat Rev Rheumatol; 2021 Apr; 17(4):213-223. PubMed ID: 33686279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.